Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)
Journal of Clinical Oncology · 2024-10 · 42 (28) · 3308-3318
DOI: 10.1200/jco.23.02261 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024-10. Verfasst von Fan Xia und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, DNA Mismatch Repair. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC). PATIENTS AND METHODS We conducted a prospective, multicenter, randomized, open-label, phase II trial using a pick-the-winner design. Eligible patients with clinical T3-4 and/or N+ rectal adenocarcinoma were randomly assigned to group A for short-course radiotherapy (SCRT) followed by six cycles of consolidation immunochemotherapy with capecitabine and oxaliplatin and toripalimab or to group B for two cycles of induction immunochemotherapy followed by SCRT and the rest four doses. Either total mesorectal excision or WW was applied on the basis of tumor response. The primary end point was CR which included pathological CR (pCR) after surgery and clinical CR (cCR) if WW was applicable, with hypothesis of an increased CR of 40% after iTNT compared with historical data of 25% after conventional TNT. RESULTS Of the 130 patients enrolled, 121 pMMR/MSS patients were evaluable (62 in group A and 59 in group B). At a median follow-up of 19 months, CR was achieved at 56.5% in group A and 54.2% in group B. Both groups fulfilled the predefined statistical hypothesis ( P < .001). Both groups reported a pCR rate of 50%. Respectively, 15 patients in each group underwent WW and remained disease free. The most frequent grade 3 to 4 toxicities were thrombocytopenia and neutropenia. Patients in group A had higher rate of cCR (43.5% v 35.6%) at restaging and lower rate of grade 3 to 4 thrombocytopenia (24.2% v 33.9%) during neoadjuvant treatment. CONCLUSION The iTNT regimens remarkably improved CR rates in pMMR/MSS LARC compared with historical benchmark with acceptable toxicity. Up-front SCRT followed by immunochemotherapy was selected for future definitive study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China.
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Oncology, Tianjin Union Medical Center, Nankai University, Tianjin, China.
- Department of Radiation Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Fan Xia, Yaqi Wang, Ruiyan Wu, Jingwen Wang, Menglong Zhou, Zhiyuan Zhang, Dan Huang, Yuxin Shen, Guoxiang Cai, Ye Xu, Zhen Zhang
Zitieren
APA
Xia, F., Wang, Y., Wang, H., Shen, L., Xiang, Z., Zhao, Y., Zhang, H., Wan, J., Zhang, H., Wang, Y., Wu, R., Wang, J., Yang, W., Zhou, M., Zhou, S., Chen, Y., Zhang, Z., Wu, X., Xuan, Y., …, & Zhang, Z. (2024). Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). Journal of Clinical Oncology, 42(28), 3308-3318. https://doi.org/10.1200/jco.23.02261
Vancouver
Xia F, Wang Y, Wang H, Shen L, Xiang Z, Zhao Y, et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). Journal of Clinical Oncology. 2024;42(28):3308-3318. doi:10.1200/jco.23.02261
BibTeX
@article{Xia2024,
author = {Xia, Fan and Wang, Yaqi and Wang, Hui and Shen, Lijun and Xiang, Zuolin and Zhao, Yutian and Zhang, Huojun and Wan, Juefeng and Zhang, Hui and Wang, Yan and Wu, Ruiyan and Wang, Jingwen and Yang, Wang and Zhou, Menglong and Zhou, Shujuan and Chen, Yajie and Zhang, Zhiyuan and Wu, Xian and Xuan, Yan and Wang, Renjie and Sun, Yiqun and Tong, Tong and Zhang, Xun and Wang, Lei and Huang, Dan and Sheng, Weiqi and Yan, Hao and Yang, Xu and Shen, Yuxin and Xu, Yu and Zhao, Ruping and Mo, Miao and Cai, Guoxiang and Cai, Sanjun and Xu, Ye and Zhang, Zhen},
title = {Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {28},
pages = {3308--3318},
doi = {10.1200/jco.23.02261}
}
EUVIMED